An investigation study of the glycemic index (GI): an open-label trial - An investigation study of the glycemic index (GI)

ORTHOMEDICO Inc.0 sites11 target enrollmentNovember 24, 2021

ConditionsHealthy Japanese subjects

Overview

Phase: 未知
Intervention: Not specified
Conditions: Healthy Japanese subjects
Sponsor: ORTHOMEDICO Inc.
Enrollment: 11
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

November 24, 2021

End Date

February 12, 2022

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Investigators

Sponsor

ORTHOMEDICO Inc.

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

•1\. Subjects who are undergoing medical treatment or have a medical history of malignant tumor, heart failure, and myocardial infarction 2\. Subjects who have a pacemaker or an implantable cardioverter defibrillator (ICD) 3\. Subjects who currently under the treatment for either cardiac arrhythmia, hepatic disorder, renal disorder, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension or other chronic diseases 4\. Subjects who have food allergies and/or food intolerances. Particularly, subjects who have lactose intolerance. 5\. Subjects who have abnormal glucose tolerance 6\. Subjects who take medications known to affect glucose tolerance 7\. Subjects who have taken insulin therapy or antihyperglycemic medication for the treatment of diabetes. 8\. Subjects who have been hospitalized for treatment or surgery within the last three months 9\. Subjects who plan to have surgery within two weeks after this trial 10\. Subjects who have or are undergoing medical treatment for diseases which influence digestion and absorption of nutrients 11\. Subjects who are taking steroids, protease inhibitors, or antipsychotics 12\. Subjects who use or take "Foods for Specified Health Uses," "Foods with Functional Claims," or other functional food/beverage in daily 13\. Subjects currently taking medicines (include herbal medicines) and supplements 14\. Subjects who are allergic to medications and/or the test\-food\-related products 15\. Subjects who are pregnant, breast\-feeding, and planning to become pregnant 16\. Subjects who suffer from COVID\-19 17\. Subjects who have been enrolled in other clinical trials within the last 28 days before the agreement to participate in this trial or plan to participate another trial during this trial 18\. Subjects who are judged as ineligible to participate in the study by the physician